Advertisement

Pharmacokinetics of lisuride after subcutaneous infusion

  • W. Krause
  • B. Nieuweboer
  • St. Ruggieri
  • F. Stocchi
  • I. Suchy
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 27)

Summary

Six parkinsonian patients received a constant subcutaneous infusion of 60 µg lisuride per hour in the abdominal region for 2 hours. Plasma levels of the unchanged drug were measured by radio-immunoassay. During infusion, a steady state plasma level of 0.78 ± 0.19ng/ml was achieved. After discontinuation of the infusion, concentrations declined with a half-life of 1.4 ± 0.4 hour. The total clearance of lisuride was 20 ± 6 ml/min/kg. Due to the low interpatient variability of plasma levels, a good control of clinical effects is to be expected.

Keywords

Plasma Level Total Clearance Unchanged Drug Parkinsonian Patient Abdominal Region 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hümpel M, Nieuweboer B, Hasan SH, Wendt H (1981) Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate; effect on plasma prolactin level. Eur J Clin Pharamcol 20: 47–51CrossRefGoogle Scholar
  2. Hümpel M, Krause W, Hoyer GA, Wendt H, Pommerenke G (1984) The pharmacokinetics and biotransformation of 14C-lisuride hydrogen maleate in rhesus monkey and man. Eur J Drug Metab Pharmacokinet 9: 347–357PubMedCrossRefGoogle Scholar
  3. Burns RSt, Gopinathan G, Hümpel M, Dorow R, Calne DB (1984) Disposition of oral lisuride in Parkinson’s disease. Clin Pharmacol Ther 35: 548–556PubMedCrossRefGoogle Scholar
  4. Dorow R, Gräf KJ, Nieuweboer B, Horowski R (1980) Intravenous lisuride: a new tool for testing responsiveness to dopamine agonists and neuroendocrine function. Acta Endocrinol [Suppl] (Copenh) 234: 9Google Scholar
  5. Parkes JD, Schachter MB, Marsden CD, Smith B, Wilson A (1987) Lisuride in Parkinsonism. Ann Neurol 9: 48–52CrossRefGoogle Scholar
  6. Stocchi F, Ruggieri S, Antonini A, Baronti F, Brughitta G, Bellantuono P, Bravi D, Agnoli A (1988) Clinical results using different modes of administration. J Neural Transm [Suppl] 27: 27–33Google Scholar
  7. Suchy I, Horowski R (1984) Use of the ergot derivative lisuride in Parkinson’s disease. In: Bergmann KJ (eds) Advances in neurology, vol 40. Raven Press, New York, p 561–568Google Scholar
  8. Luquin MR, Obeso JA, Martinez-Lage MJ, Tresguerres J, Parada J, Nieuweboer B, Dorow R, Horowski R (1986) Parenteral administration of lisuride in Parkinson’s disease. In: Baker MD, Hassler RG (eds) Advances in neurology, vol 45. Raven Press, New York, p515–521Google Scholar
  9. Obeso JA, Luquin MR, Martinez-Lage MJ (1986) Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson’s disease. Lancet 2: 467–470CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • W. Krause
    • 1
  • B. Nieuweboer
    • 1
  • St. Ruggieri
    • 2
  • F. Stocchi
    • 2
  • I. Suchy
    • 1
  1. 1.Research Laboratories of ScheringBerlin and BergkamenFederal Republic of Germany
  2. 2.Department of Neurological ScienceUniversity of Rome “La Sapienza”RomeItaly

Personalised recommendations